Bristol-Myers Squibb (BMY) Said to Place $142,000/Year Price Tag on Empliciti

Bristol-Myers Squibb (NYSE: BMY) is said to place a $142,000 per year price on its recently-approved multiple myeloma treatment, Empliciti.

FiercePharma noted the cost in a post today.

The treatment will run about $10,000 per month.

Bristol-Myers Squibb said the price is based on the value Empliciti will deliver to patients and society, the number of patients affected by the disease, and negotiations with payers and local authorities. The company will also work with patients who have afforability issues.

Empliciti was developed in conjunction with AbbVie (NYSE: ABBV).

You May Also Be Interested In

• Bristol-Myers Squibb (BMY) stock slips despite earnings beat
• HOOKIPA Pharma Inc. (HOOK) Receives FDA Clearance of INDA for HB-700
• ImmunityBio (IBRX) Announces Positive OS Results of Anktiva Combined With Checkpoint Inhibitors in NSLC